ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Wednesday, November 15, 2023

7:30AM-9:00AM: Abstract Number: L19

A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks

Late-Breaking Abstract Session

7:30AM-9:00AM: Abstract Number: L15

AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography

Late-Breaking Abstract Session

7:30AM-9:00AM: Abstract Number: L18

Immune-metabolic Heterogeneity and Clinical Implications in Primary Sjogren’s Syndrome Revealed by Molecular Classification of Salivary Glands

Late-Breaking Abstract Session

7:30AM-9:00AM: Abstract Number: L17

Safety, Tolerability, and Exploratory Efficacy of Afimetoran, a TLR7/8 Inhibitor, in Patients with Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study

Late-Breaking Abstract Session

7:30AM-9:00AM: Abstract Number: L20

Telitacicept, a Human Recombinant Fusion Protein Targeting and Neutralizing B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Rheumatoid Arthritis (RA) Patients with an Inadequate Response to Methotrexate (MTX): A Randomized, Double-Blind, Phase 3 Study

Late-Breaking Abstract Session

7:30AM-9:00AM: Abstract Number: L16

Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease (WInS IgG4-RD): An Investigator-initiated, Multi-center, Open-label, Randomized Controlled Trial

Late-Breaking Abstract Session

9:00AM-10:30AM: Abstract Number: 2575

Accurate Stratification of Cancer Risk in a Real-World Cohort Using the International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

9:00AM-10:30AM: Abstract Number: 2567

An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases

Abstracts: Epidemiology & Public Health III

9:00AM-10:30AM: Abstract Number: 2574

Are Patients Classified as IPAF More Likely to Also Meet SLE Criteria by 2019 EULAR/ACR Than by SLICC?: An Abstract

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III

9:00AM-10:30AM: Abstract Number: 2572

Autoantibody Profile of Autoimmune Driven Interstitial Lung Disease as Compared to Idiopathic Pulmonary Fibrosis and Association of Autoantibodies with Survival

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III

9:00AM-10:30AM: Abstract Number: 2563

Causal Associations Between Gut Microbiota and Rheumatic Diseases: A Mendelian Randomization Study

Abstracts: Epidemiology & Public Health III

9:00AM-10:30AM: Abstract Number: 2566

Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database

Abstracts: Epidemiology & Public Health III

9:00AM-10:30AM: Abstract Number: 2569

Efficacy and Safety of Therapeutic Interventions for the Treatment of Still’s Disease: A Systematic Review and Meta-analysis Informing the EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III

9:00AM-10:30AM: Abstract Number: 2568

First Breakthrough COVID-19 Infection Following Two SARS-CoV-2 Vaccinations Among Primary Systemic Vasculitis Patients

Abstracts: Epidemiology & Public Health III

9:00AM-10:30AM: Abstract Number: 2577

Frequency of Atherosclerotic Cardiovascular Disease Following a Diagnosis of Idiopathic Inflammatory Myopathy: Data from a Large National Registry

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].